Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canadian dollar notches a two-year high on higher oil prices

12/02/2020 | 04:09pm EST
FILE PHOTO: A Canadian dollar coin, commonly known as the

TORONTO (Reuters) - The Canadian dollar edged higher against its U.S. counterpart on Wednesday, as hopes rose that major oil producers will maintain production limits next year and the prospect of a coronavirus vaccine supported investor sentiment.

The loonie was up 0.1% at 1.2922 per U.S. dollar, or 77.39 U.S. cents. The currency touched its strongest intraday level since October 2018 at 1.2916.

The Canadian dollar got a boost "as oil prices rallied following reports OPEC may be near a deal to extend production caps through Q1 (the first quarter) of 2021," Ronald Simpson, managing director, global currency analysis at Action Economics, said in a note.

Canada is a major producer of oil, which settled 1.6% higher at $45.28 a barrel.

Britain's approval of a COVID-19 vaccine boosted hopes for a demand recovery, adding to support for crude. It also helped keep global stock markets near record highs.

Canadian health authorities should soon complete their regulatory review of Pfizer Inc's vaccine candidate, Health Minister Patty Hajdu said.

Canadian labor productivity fell by a record 10.3% in the third quarter, as hours worked rebounded faster than business output, Statistics Canada said. That follows a record increase in the second quarter, which was marked by lockdown measures imposed because of the coronavirus pandemic.

Canada's jobs report for November is due on Friday, which could help guide expectations for the Bank of Canada policy outlook. The central bank, which has cut its benchmark interest rate to a record low of 0.25%, is due to make a policy decision next week.

Canadian government bond yields were higher across the curve, with the 10-year up 3 basis points at 0.767%. It touched its highest intraday level since Nov. 13 at 0.780%.

(Reporting by Fergal Smith; Editing by Jonathan Oatis and Peter Cooney)

By Fergal Smith

© Reuters 2020
All news about PFIZER INC.
12:03pPFIZER : Canadian provinces push back vaccination plans as Pfizer deliveries gri..
11:50aModerna Developing Vaccine Booster Shot Against Virus Strain First Identified..
11:07aTHE LATEST : Moderna will test booster dose for virus variant
10:06aEXCLUSIVE : Pfizer wants India to order COVID-19 vaccine before pursuing approva..
10:02aPfizer, which has sought emergency use authorisation for covid-19 vaccine in ..
10:02aPfizer says it needs purchase commitment from india for covid-19 vaccine befo..
09:13aMerck ends development of two potential COVID-19 vaccines
08:42aPFIZER : China pushes conspiracy theories on COVID origin, vaccines
08:00aPfizer Seeks South Korean Approval for COVID-19 Vaccine
08:00aU.S. goal to squeeze more COVID shots from Pfizer vials hampered by syringe p..
More news
Financials (USD)
Sales 2020 48 216 M - -
Net income 2020 19 801 M - -
Net Debt 2020 43 531 M - -
P/E ratio 2020 11,8x
Yield 2020 3,98%
Capitalization 203 B 203 B -
EV / Sales 2020 5,12x
EV / Sales 2021 4,43x
Nbr of Employees 88 300
Free-Float 59,1%
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 41,93 $
Last Close Price 36,55 $
Spread / Highest target 45,0%
Spread / Average Target 14,7%
Spread / Lowest Target -1,50%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-0.71%203 159
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
ABBVIE INC.3.46%195 720